Long-Acting Interferon Therapy Approved for Essential Thrombocythemia M. Alexander Otto, PA, MMSc

https://www.medscape.com/viewarticle/long-acting-interferon-therapy-approved-essential-2026a1000vet?src= The FDA has approved ropeginterferon alfa-2b injection (BESREMi, PharmaEssentia) for the treatment of adults with essential thrombocythemia (ET). Ropeginterferon is the first new FDA-approved treatment for ET in nearly three decades, PharmaEssentia said in a press release. ET is a rare blood disorder that causes the bone marrow to make too many platelets, which increases the risk for blood clots and bleeding.